22 enero 2013

STROKE. Clinical Sciences. Neuroimaging Findings in Cryptogenic Stroke Patients With and Without Patent Foramen Ovale

David E. Thaler, MD, PhD; Robin Ruthazer, MPH; Emanuele Di Angelantonio, MD, MSc; Marco R. Di Tullio, MD; Jennifer S. Donovan, MS; Mitchell S.V. Elkind, MD, MS; John Griffith, PhD; Shunichi Homma, MD, FACC; Cheryl Jaigobin, MD, FRCP, MSc; Jean-Louis Mas, MD; Heinrich P. Mattle, MD; Patrik Michel, MD; Marie-Luise Mono, MD; Krassen Nedeltchev, MD, FESC; Federica Papetti, MD; Joaquín Serena, MD, PhD; Christian Weimar, MD; David M. Kent, MD, CM, MSc

Background and Purpose: Patent foramen ovale (PFO) and cryptogenic stroke are commonly associated but some PFOs are incidental. Specific radiological findings associated with PFO may be more likely to indicate a PFO-related cause. We examined whether specific radiological findings are associated with PFO among subjects with cryptogenic stroke and known PFO status.

21 marzo 2014

EUROPEAN HEART JOURNAL. In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study

Jin M. Cheng†, Hector M. Garcia-Garcia†,*, Sanneke P.M. de Boer, Isabella Kardys, Jung Ho Heo, K. Martijn Akkerhuis, Rohit M. Oemrawsingh, Ron T. van Domburg, Jurgen Ligthart, Karen T. Witberg, Evelyn Regar, Patrick W. Serruys, Robert-Jan van Geuns and Eric Boersma

Aims: Acute coronary syndromes (ACS) are mostly caused by plaque rupture. This study aims to investigate the prognostic value of in vivo detection of high-risk coronary plaques by intravascular ultrasound (IVUS) in patients undergoing coronary angiography.

21 marzo 2014

EUROPEAN HEART JOURNAL. Family history of premature cardiovascular disease: blood pressure control and long-term mortality outcomes in hypertensive patients

Catherine Williamson1,†, Panniyammakal Jeemon1,†, Claire E. Hastie1, Linsay McCallum1, Scott Muir1, Jesse Dawson1, Matthew Walters1, William Sloan2, David Morrison2, Anna F. Dominiczak1, Jill Pell2 and Sandosh Padmanabhan1,*

Aims: Current guidelines recommend early referral and initiation of intensive cardiovascular (CV) risk reduction in individuals with a positive family history of coronary heart disease (CHD). We hypothesized that a family history of premature CHD and stroke [CV disease (CVD)] would lead to earlier referral of hypertensive patients to secondary care clinic, leading to better control of risk factors, mitigating the excess risk seen in these individuals.

21 marzo 2014

EUROPEAN HEART JOURNAL. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study)

Lluís Mont1,*, Felipe Bisbal1, Antonio Hernández-Madrid2, Nicasio Pérez-Castellano3, Xavier Viñolas4, Angel Arenal5, Fernando Arribas6, Ignacio Fernández-Lozano7, Andrés Bodegas8, Albert Cobos9, Roberto Matía2, Julián Pérez-Villacastín3, José M. Guerra4, Pablo Ávila5, María López-Gil6, Victor Castro7, José Ignacio Arana8, Josep Brugada1, on behalf of SARA investigators

Background: Catheter ablation (CA) is a highly effective therapy for the treatment of paroxysmal atrial fibrillation (AF) when compared with antiarrhythmic drug therapy (ADT). No randomized studies have compared the two strategies in persistent AF. The present randomized trial aimed to compare the effectiveness of CA vs. ADT in treating persistent AF.

01 marzo 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Transcatheter closure of perimembranous ventricular septal defect with the Amplatzer® membranous VSD occluder 2: Initial world experience and one-year follow-up

Apostolos Tzikas MD, PhD1, Reda Ibrahim MD1, Daniel Velasco-Sanchez MD2, Xavier Freixa MD, PhD1, Marcela Alburquenque MD3, Paul Khairy MD, PhD1, John L. Bass MD4, Juan Ramirez MD5, Daniel Aguirre MD3 andJoaquim Miro MD2,*

Objectives: To describe the initial world experience and mid-term follow-up of perimembranous ventricular septal defect (pmVSD) closure with a newly designed occluder.

15 febrero 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. A novel biodegradable stent applicable for use in congenital heart disease: Bench testing and feasibility results in a rabbit model

Surendranath R. Veeram Reddy MD1,*, Tre R. Welch PhD2, Jian Wang MD, PhD2, Frederic Bernstein DO3, James A. Richardson MD4, Joseph M. Forbess MD2 andAlan W. Nugent MBBS1

Objectives: A novel double opposed helical (DH) biodegradable stent was designed and fabricated for CHD applications. The primary objective was to evaluate the feasibility of DH stent delivery and deployment in rabbit external iliac arteries (EIA). Secondary objectives were to assess stent patency, thrombosis and inflammation at 1-week and 1-month follow-up.

01 marzo 2013

JACC. Population Trends in Percutaneous Coronary Intervention. 20-Year Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

Marieke L. Fokkema, MD⁎; Stefan K. James, MD, PhD†; Per Albertsson, MD, PhD‡; Axel Akerblom, MD†; Fredrik Calais, MD§; Peter Eriksson, MD, PhD∥; Jens Jensen, MD, PhD¶; Tage Nilsson, MD, PhD#; Bart J. de Smet, MD, PhD⁎; Iwar Sjögren, MD⁎⁎; Björn Thorvinger, MD††; Bo Lagerqvist, MD, PhD†

Objectives: The aim of this study was to describe the characteristics and outcome of all consecutive patients treated with percutaneous coronary intervention (PCI) in an unselected nationwide cohort over the past 2 decades.

01 marzo 2013

JACC. Progression of Coronary Calcium and Incident Coronary Heart Disease Events. MESA (Multi-Ethnic Study of Atherosclerosis)

Matthew J. Budoff, MD⁎; Rebekah Young, PhD†; Victor A. Lopez, MS‡; Richard A. Kronmal, PhD†; Khurram Nasir, MD, MPH⁎; Roger S. Blumenthal, MD§; Robert C. Detrano, MD, PhD‡; Diane E. Bild, MD, MPH⁎⁎; Alan D. Guerci, MD††; Kiang Liu, PhD‡‡; Steven Shea, MD§§; Moyses Szklo, MD∥∥; Wendy Post, MD§; Joao Lima, MD§; Alain Bertoni, MD, MPH¶¶; Nathan D. Wong, PhD, MPH‡

Objectives: The study examined whether progression of coronary artery calcium (CAC) is a predictor of future coronary heart disease (CHD) events.

01 marzo 2014

AMERICAN HEART JOURNAL. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study

Alexander T. Cohen, MD, Robert Harrington, MD, Samuel Z. Goldhaber, MD, Russell Hull, MD, C. Michael Gibson, MD, Adrian F. Hernandez, MD, MHS, Michael M. Kitt, MD, Todd J. Lorenz, MD

Randomized clinical trials have identified a population of acute medically ill patients who remain at risk for venous thromboembolism (VTE) beyond the standard duration of therapy and hospital discharge. The aim of the APEX study is to determine whether extended administration of oral betrixaban (35–42 days) is superior to a standard short course of prophylaxis with subcutaneous enoxaparin (10 ± 4 days followed by placebo) in patients with known risk factors for post-discharge VTE. Patients initially are randomized to receive either betrixaban or enoxaparin (and matching placebo) in a double dummy design. Following a standard duration period of enoxaparin treatment (with placebo tablets) or betrixaban (with placebo injections), patients receive only betrixaban (or alternative matching placebo).

01 marzo 2014

AMERICAN HEART JOURNAL. Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry

Emily C. O’Brien, PhDemail address, Matthew T. Roe, MD, MHS, Elizabeth S. Fraulo, BSN, Eric D. Peterson, MD, MPH, Christie M. Ballantyne, MD, Jacques Genest, MD, Samuel S. Gidding, MD, Emma Hammond, BSc, PhD, Linda C. Hemphill, MD, Lisa C. Hudgins, MD, Iris Kindt, MD, MPH, Patrick M. Moriarty, MD, Joyce Ross, MSN, CRNP, James A. Underberg, MD, Karol Watson, MD, Dave Pickhardt, MBA, Daniel J. Rader, MD, Katherine Wilemon, BS, Joshua W. Knowles, MD, PhD

Background: Familial hypercholesterolemia (FH) is a hereditary condition caused by various genetic mutations that lead to significantly elevated low-density lipoprotein cholesterol levels and resulting in a 20-fold increased lifetime risk for premature cardiovascular disease. Although its prevalence in the United States is 1 in 300 to 500 individuals, <10% of FH patients are formally diagnosed, and many are not appropriately treated. Contemporary data are needed to more fully characterize FH disease prevalence, treatment strategies, and patient experiences in the United States.

01 marzo 2014

AMERICAN HEART JOURNAL. Hospital patterns of medical management strategy use for patients with non–ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease

Ralf E. Harskamp, MD, Tracy Y. Wang, MD, MHS, MSc, Deepak L. Bhatt, MD, MPH, Stephen D. Wiviott, MD, Ezra A. Amsterdam, MD, Shuang Li, MS, Laine Thomas, PhD, Robbert J. de Winter, MD, PhD, Matthew T. Roe, MD, MHS

Background: Patients with non–ST-elevation myocardial infarction (NSTEMI) and three-vessel or left main coronary disease (3VD/LMD) have a high risk of long-term mortality when treated with a medical management strategy (MMS) compared with revascularization.

01 marzo 2014

AMERICAN HEART JOURNAL. The impact of residual coronary lesions on clinical outcomes after percutaneous coronary intervention: Residual SYNTAX score after percutaneous coronary intervention in patients from the Efficacy of Xience/Promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) registry

Kyung Woo Park, MD, PhD, Jeehoon Kang, MD, Si-Hyuck Kang, MD, Hyo-Suk Ahn, MD, Hyun-Jae Kang, MD, PhD, Bon-Kwon Koo, MD, PhD, In-Ho Chae, MD, PhD, Tae-Jin Youn, MD, PhD, Byung-Hee Oh, MD, PhD, Young-Bae Park, MD, PhD, David Kandzari, MD, Hyo-Soo Kim, MD, PhD

Background: The SYNTAX score (SS) is used in preprocedural evaluation for percutaneous coronary intervention (PCI); it assesses the complexity of coronary lesions and predicts PCI outcome. However, the usefulness of the residual SS (rSS), which can be calculated after PCI and may reflect the completeness of revascularization, has not been fully investigated in an enriched PCI population.

01 marzo 2014

AMERICAN HEART JOURNAL. Comparison of percutaneous coronary intervention for previously treated versus de novo culprit lesions in acute myocardial infarction patients: insights from the National Cardiovascular Data Registry

Chee Tang Chin, MBChB, MRCP(UK), John C. Messenger, MD, David Dai, PhD, Lisa A. McCoy, MS, Michael A. Kutcher, MD, H. Vernon Anderson, MD, Matthew T. Roe, MD, MHS, Tracy Y. Wang, MD, MHS, MSc

Background: Little is known about percutaneous coronary intervention (PCI) outcomes among patients presenting with an acute myocardial infarction (MI) with a history of prior PCI. Outcomes may differ depending on whether PCI is performed on a previously treated or de novo culprit lesion.

01 marzo 2014

AMERICAN HEART JOURNAL. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: A meta-regression analysis of randomized trials

Giuseppe Tarantini, MD, PhD, Sorin Jakob Brener, MD, Alberto Barioli, MD, Andrea Gratta, MD, Guido Parodi, MD, Roberta Rossini, MD, PhD, Eliano Pio Navarese, MD, PhD, Giampaolo Niccoli, MD, PhD, Anna Chiara Frigo, MSc, Giuseppe Musumeci, MD, Sabino Iliceto, MD, Gregg Whitney Stone, MD

Background: Bivalirudin significantly reduces 30-day major and minor bleeding compared with unfractionated heparin (UFH), while resulting in similar or lower rates of ischemic events in both patients with stable and unstable coronary disease undergoing percutaneous coronary intervention. We performed a meta-analysis of randomized trials to evaluate the impact of bivalirudin compared with UFH, with or without glycoprotein IIb/IIIa receptor inhibitors (GPI), on the rates of mortality, myocardial infarction (MI), and major bleeding.

21 marzo 2014

EUROPEAN HEART JOURNAL. CardioPulse Articles. The past, present, and future of bioresorbable vascular scaffolds

Patrick W. Serruys

The history of bioresorbable vascular scaffolds (BVS) began in 1988 when the biodegradable scaffold was developed by the Thoraxcenter in Rotterdam, the Netherlands, and Duke University in Durham, North Carolina.